Intravitreous treatment of severe ocular von Hippel–Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial is a research paper published in Clinical and Experimental Ophthalmology (2021). On theSindex it has a DataRank of 0. It has been cited 15 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: HHSN263201200001C
NIH HHS
Grant: HHSN263201200001E
Intramural NIH HHS
Grant: ZIA BC011028
Heed Ophthalmic Foundation
FWCI
0.47
Citation Percentile
0.5%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals